Recent Finacing
Recent Raise
Aera builds a protein nanoparticle delivery platform using endogenous retroelement-derived capsid-like proteins to package and deliver nucleic acids across tissues and licenses compact programmable gene-editing enzymes.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Aera Therapeutics.
